Clinical trials: Genital Neoplasm
Prostate Cancer
PK and Dose Escalation and Expansion Study of DST-2970
This is a Phase I multi-center, open-label, study of DST-2970 to determine the MTD, overall safety/tolerability, PK/pharmacodynamic parameters, and efficacy in prostate cancer patients.The study will include a dose escalation…
- Trial name
- NCT04291664
- Testing
- Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- DisperSol Technologies, LLC
Ovarian Cancer
Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR)…
- Trial name
- NCT03519230
- Testing
- Pamiparib capsule
- Where
- 28 sites in China
- Volunteers
- 224 people
- Sponsor
- BeiGene
Prostate Cancer
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with…
- Trial name
- NCT02130700
- Testing
- VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Innocrin Pharmaceutical
Advanced Solid Tumors
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
- Trial name
- NCT00603356
- Testing
- OSI-930 and erlotinib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
Polycystic Ovary Syndrome
Diamel in the Treatment of Polycystic Ovary Syndrome
The purpose of this study is to assess the efficacy of Diamel administration in the treatment of Polycystic Ovary Syndrome. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks.
- Trial name
- NCT01051024
- Testing
- Diamel
- Where
- Cuba
- Volunteers
- 110 people
- Sponsor
- Catalysis SL
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Neoplasms
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02222922
- Testing
- PF-06647020 Q3W, fluconazole, PF-06647020 Q2W
- Where
- 17 sites in United States, Spain
- Volunteers
- 138 people
- Sponsor
- Pfizer
Prostate Cancer
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients
In this observational study, blood samples for pharmacokinetic (PK) testing will be collected from subjects with metastatic prostate cancer during their treatment with docetaxel.
- Trial name
- NCT02376296
- Testing
- docetaxel, Blood draws
- Where
- 20 sites in United States
- Volunteers
- 35 people
- Sponsor
- Saladax Biomedical, Inc.
Cancer, Non Small Cell Lung Cancer
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.
- Conditions
- Cancer, Non Small Cell Lung Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT01000896
- Testing
- AZD0530, Carboplatin, paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Cervical Intraepithelial Neoplasia
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
This study was designed to enable all subjects who received placebo in the HPV-039 study (NCT00779766), to also receive GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed.
- Trial name
- NCT03629886
- Testing
- HPV (Types 16, 18) Vaccine, Adsorbed
- Where
- 4 sites in China
- Volunteers
- 6,051 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
METASTATIC CERVICAL CANCER
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
This study is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study in 498 patients with persistent, recurrent or metastatic cervical cancer.Experimental: QL1706 + Chemotherapy…
- Trial name
- NCT05446883
- Testing
- QL1706, Paclitaxel injection, Cisplatin/Carboplatin
- Where
- 3 sites in China
- Volunteers
- 498 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hot Flashes, Prostate Cancer
Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes.
- Trial name
- NCT00005623
- Testing
- cyproterone acetate, quality-of-life assessment
- Where
- United States
- Sponsor
- Barr Laboratories
Prostate Cancer
A Study of SHR-4394 Injection in Subjects With Prostate Cancer
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.
- Trial name
- NCT06783829
- Testing
- SHR4394
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Mycoses, HIV Infections
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment for biopsy proven fungal infections in major organs, disseminated infection, suspected fungal infection and fungemia in adult…
- Trial name
- NCT00002277
- Testing
- Fluconazole, Amphotericin B
- Where
- 3 sites in United States
- Sponsor
- Pfizer
Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction
A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets
To assess the relative bioavailability of SHR7280 dry suspension and tablets in healthy subjects. To assess the safety and tolerability of a single dose of SHR7280 dry suspension and tablets.
- Trial name
- NCT05868057
- Testing
- SHR7280 tablets, SHR7280 dry suspension
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Fallopian Tube Cancer, Ovarian Cancer
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
To determine if AMG 386 plus pegylated liposomal doxorubicin (PLD) is superior to placebo plus PLD as measured by progression-free survival (PFS) The hypothesis for this study is that AMG 386 plus PLD will prolong PFS compared to…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01281254
- Testing
- AMG386 plus PLD
- Where
- 106 sites in United States, Australia and 16 more
- Volunteers
- 223 people
- Sponsor
- Amgen
Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
This trial is an open, multicenter, phase II clinical trial to evaluate the efficacy and safety of Utidelone capsules in patients with advanced solid tumors.
- Conditions
- Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer, Bile Duct Cancer
- Trial name
- NCT06730581
- Testing
- Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelone Capsule
- Volunteers
- 100 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Ovarian Neoplasms
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.
- Trial name
- NCT00052065
- Testing
- TLK286
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Telik
Prostate Cancer
Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate
Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate.
- Trial name
- ANES (NCT00919022)
- Testing
- Cyproterone Acetate (Androcur, BAY94-8367)
- Where
- Czechia
- Volunteers
- 194 people
- Sponsor
- Bayer
Breast Cancer, Prostate Cancer
Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
- Conditions
- Breast Cancer, Prostate Cancer, Bone Neoplasms
- Trial name
- NCT00558272
- Testing
- AZD0530, Zoledronic Acid
- Where
- 28 sites in United States, Canada and 6 more
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.